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Abstract
Background: Decompensated cirrhosis is associated with a poor prognosis and liver transplantation provides the only
curative treatment option with excellent long-term results. The relative shortage of organ donors renders the allocation
algorithms of organs essential. The optimal strategy based on scoring systems and/or waiting time is still under debate.
Methods: Data sets of 268 consecutive patients listed for single-organ liver transplantation for nonfulminant liver disease
between 2003 and 2005 were included into the study. The Model for End-Stage Liver Disease (MELD) and Child-
Turcotte-Pugh (CTP) scores of all patients at the time of listing were used for calculation. The predictive ability not only
for mortality on the waiting list but also for the need for withdrawal from the waiting list was calculated for both scores.
The Mann-Whitney-U Test was used for the univariate analysis and the AUC-Model for discrimination of the scores.
Results: In the univariate analysis comparing patients who are still on the waiting list and patients who died or were
removed from the waiting list due to poor conditions, the serum albumin, bilirubin INR, and CTP and MELD scores as
well as the presence of ascites and encephalopathy were significantly different between the groups (p < 0.05), whereas
serum creatinine and urea showed no difference.
Comparing the predictive abilities of CTP and MELD scores, the best discrimination between patients still alive on the
waiting list and patients who died on or were removed from the waiting list was achieved at a CTP score of ≥9 and a
MELD score of ≥14.4. The sensitivity and specificity to identify mortality or severe deterioration for CTP was 69.0% and
70.5%, respectively; for MELD, it was 62.1% and 72.7%, respectively. This result was supported by the AUC analysis
showing a strong trend for superiority of CTP over MELD scores (AUROC 0.73 and 0.68, resp.; p = 0.091).
Conclusion: The long term prediction of mortality or removal from waiting list in patients awaiting liver transplantation
might be better assessed by the CTP score than the MELD score. This might have implications for the development of
new improved scoring systems.
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Liver transplantation (LTx) provides the only curative
treatment option with excellent long-term results in
patients with decompensated cirrhosis of the liver [1]. The
Child-Turcotte-Pugh (CTP) score [2], originally devel-
oped for the assessment of the outcome of patients with
cirrhosis and portal hypertension, was extended for gen-
eral prognosis, and to stratify patients on the waiting list
for LTx [1].
The use of CTP in prioritizing potential liver transplant
recipients is limited by several factors: the variables,
ascites and encephalopathy, are all subjective and are
influenced by medical therapy. The lack of an assessment
of renal function, which is a reliable prognostic marker in
cirrhosis, is an additional limiting factor [3].
The Model for End-Stage Liver Disease (MELD) is a scor-
ing system for the severity of liver disease initially devel-
oped as a model in predicting poor survival in patients
after transjugular intrahepatic porto-systemic shunt
(TIPS). [4,5]. A modification of this score was developed
to predict mortality in patients with cirrhosis of different
etiologies and severities of liver disease [6]. This MELD
score was found to be superior to the CTP score in predict-
ing 3-months mortality and therefore the MELD score was
implemented in 2002 in the United States for the prioriti-
zation of LTx recipients.
However, the MELD score has been criticized for several
different reasons. Some studies have revealed marked var-
iations in serum creatinine measurement when different
laboratory methodologies are used [7]. INR was designed
to standardize the anticoagulation effect of warfarin and
may not reflect the severity of liver disease [8]. Two studies
that used different assays to measure INR led to signifi-
cantly different MELD scores between transplant centers
[9].
In countries within the alliance of Eurotransplant, the
MELD score for prioritization of patients awaiting Ltx was
initiated in November 2006 and at present little informa-
tion is available concerning the prognostic ability of this
allocation system compared to the previous system, which
was based on CTP score and waiting time.
In this retrospective analysis, we evaluate the MELD score
in comparison to the CTP score in order to better assess
the prognostic ability of these different methods in pre-
dicting mortality on the waiting list as well as the need for
removal from waiting list due to deterioration of the over-
all clinical condition.
Methods
Data sets of 268 consecutive patients listed for single-
organ LTx for nonfulminant liver disease between 2003
and 2005 were included in the study. Baseline characteris-
tics of patients included age, gender, body mass index, eti-
ology of liver disease and clinically relevant comorbidity
(Table 1).
(N = 20) patients who underwent re-transplantation for
recurrent disease with cirrhosis after previous transplanta-
tion were included in the trial, whereas patients with early
graft failure without cirrhosis of the graft at the time of
listing for re-transplantation were not included.
The CTP includes two clinical variables, ascites and
encephalopathy, and three laboratory parameters, serum
bilirubin, albumin and prothrombine time. Each variable
is scored from 1 to 3 with the sum of each scored variable
representing the CTP score. The MELD score was calcu-
lated using the model previously described [6]. MELD and
CTP scores for all patients at the time of listing were used
for calculation.
The predictive abilities of CTP and MELD scores not only
for mortality on the waiting list but also for the need for
withdrawal from the waiting list were calculated.
All analyses were performed using SPSS 16.0 (SPSS Inc.
Chicago, IL). The Mann-Whitney-U Test was used for the
univariate analysis and the AUC-Model for discrimination
of the scores.
The study protocol conformed to the ethical guidelines of
the Helsinki Declaration, and was approved by the ethics
committee of the University of Heidelberg.
Results
Clinical characteristics and demographic data of patients
included in the study are shown in Table 1. The mean age
of patients was 50.5 years (range 16 to 68 years). Of the
268 patients, 99 were female and 169 were male. The
mean body mass index was 25.1 (range 14.5-40.4).
Approximately one-third of patients suffered from alco-
holic liver disease and another one-third from virus hepa-
titis-induced cirrhosis, respectively. Malignancies and
cholestatic liver disease accounted for 14.5% and 7.8%,
respectively. Other etiologies accounted for 20.2%.
Ascites, encephalopathy and hepatorenal syndrome as
complications of liver cirrhosis were noted in 26%, 29%
and 5.6% of patients, respectively. Other comorbidity fac-
tors not associated with the underlying liver disease were
diabetes (23.1%), coronary heart disease (3.7%), hyper-
tension (15.3%) and renal failure other than hepatorenal
syndrome (12.7%).
The mean time on waiting list for the whole cohort of
patients was 357 days (range 9 to 1836 days). 37 patients
were removed from the waiting list: 23 patients died, sixPage 2 of 7
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patients improved and liver transplantation was no longer
considered to be indicated, and two patients retracted
their agreement to transplantation. The 23 patients who
died and the 6 patients who were removed for poor con-
ditions were included into the calculation for the predic-
tive ability of the two scores (Table 2).
During the study period, 100 of the 268 patients were suc-
cessfully transplanted.
The mean MELD score of all patients was 14.2 (range 6.4
to 40), the mean CTP score was 8.0 (range 5 to 14).
In the univariate analysis comparing patients still on the
waiting list and patients who died or were removed due to
poor conditions, serum albumin, bilirubin INR, and CTP
and MELD scores as well as the presence of ascites and
encephalopathy were significantly different between the
groups (p < 0.05), whereas serum creatinine and urea
were not different (Table 3).
Table 1: Baseline characteristics parameters at the time of listing
N/Mean SD, (Range),% 95% CI of mean
Patients 268
Age (years) 50.54 11.32 (16 - 68) 49.2-51.9
Female/Male 99/169
BMI 25.1 4.5 (14.5 - 40.4) 24.5-25.7
Etiology of liver disease
Cirrhosis - alcoholic 79 29.5
Cirrhosis - viral 75 28.0
other 54 20.2
malignancy 39 14.5
Cholestatic liver disease 21 7.8
Co-morbidity
Diabetes 62 23.1
Coronary heart disease 10 3.7
Hypertension 41 15.3




MELD score 14.2 6.4 (6.4 - 40) 13.4-14.9
CTP score 8.0 8.0 (5 - 14) 7.8-8.3
Table 2: Events on waiting list
n % t
Days on waiting list 357 ± 328 (9-1836) 328 1





Mortality and removed due to poor conditions 17.2
Tx 100 37.3Page 3 of 7
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scores, discrimination between patients still alive on the
waiting list and patients who died or were removed was
determined by minimizing the false positive and false
negative results of each score. Patient who underwent
transplantation during the observation period were
excluded for this analysis. Of 29 patients who died or were
removed from the waiting list a CTP score of ≥9 identified
20 patients and a MELD score of ≥14.4 identified 18
patients (Figure 1). Of the 139 patients still on the waiting
list a CTP score of < 9 correctly identified 98 patients, the
MELD score of < 14.4 101 patients. The sensitivity and
specificity to identify mortality or severe deterioration was
69.0% and 70.5% for CTP, respectively; MELD achieved
only a 62.1% sensitivity and a 72.7% specificity (Tables 4,
5 and 6). Discrimination was achieved by CTP with a p
value of 0.00009 versus MELD with a p value of 0.002.
The area under ROC of the MELD score was 0.68 and of
CTP score it was 0.73 (c-statistics; p = 0.091). Although
the difference was not statistically significant, a trend to
superiority of CTP was observed, supporting the results of
the univariate discrimination analysis. (Figure 2).
Discussion
Increased mortality of patients on the waiting list for LTx
and shortage of donor organs gave rise to efforts to
improve allocation criteria for liver transplantation candi-
Table 3: Mortality on waiting list or removed from waiting list due to poor conditions (patients with Tx excluded) univarate analysis
Still on waiting list (n = 139) Died or removed from waiting list (n = 29) P value
Mean ± SD (95% CI) Mean ± SD (95% CI)
Albumin [g/l] 34.9 ± 11.3 (33.1-36.8) 24.3 ± 12.4 (19.6-29.1) 0.0001
Bilirubin [mg/dl] 2.9 ± 3.5 (2.4-3.6) 6.5 ± 9.1 (3.0-10.0) 0.004
INR 1.25 ± 0.2 (1.2-1.3) 1.56 ± 0.34 (1.3-1.6) 0.0001
Creatinine [mg/dl] 1.04 ± 0.8 (0.8-1.3) 1.57 ± 3.1 (0.4-2.7) Ns
Urea [mg/dl] 32.0 ± 18.4 (29.0-35.2) 41.5 ± 26.0 (28.2-54.8) Ns
CTP score 7.5 ± 1.8 (7.2-7.8) 9.4 ± 2.4 (8.5-10.3) 0.0001
MELD score 13.2 ± 5.9 (12.1-14.1) 17.2 ± 7.4 (14.4-20.1) 0.002
Ascites 1:112 (81%) 1:20 (69%) Ns
2:20 (14%) 2:6 (21%)
3:7 (5%) 3:3 (10%)
HE 1:107 (77%) 1:19 (65%) Ns
2:31 (22%) 2:9 (31%)
3:1 (1%) 3:1 (4%)
Combined calculation of ascites plus HE showed no difference
Ascites and HE were classified from stage 1 to 3
Table 4: Differentiation of CTP and MELD scores (no Tx)
CTP Score <9 CTP Score ≥9 MELD Score <14.4 MELD score ≥14.4
Still on waiting list 98 41 101 38
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United States for prioritization in 2002, and within the
alliance of Eurotransplant November 2006.
In this retrospective analysis, we evaluated the MELD
score in comparison to the CTP score in order to assess the
prognostic ability of these different methods in predicting
mortality on the waiting list as well as the need for the
removal from waiting list due to deterioration of the over-
all clinical condition. The latter condition had not been
regularly assessed in prior studies evaluating MELD and
CTP scores. Interestingly one study which analyzed wait-
ing list mortality in this respect showed similar predictive
value of MELD and CTP for waiting list mortality [10].
In our study, which comprised an observation period of
approximately one year, MELD was not shown to be supe-
rior to CTP. In fact, we found that CTP actually yielded
better discrimination of patients for this forecasting hori-
zon. This is in contrast to most other studies, which have
focused on a prediction of 3-months mortality. Both
scores performed well in discriminating, but in our study
a CTP cut off of 9 classified more patients correctly in
either the survival group or the mortality/removal group
than the best MELD cut off of 14.4. This was reflected by
the higher level of significance of CTP compared to MELD.
In addition most studies did not take into account
patients removed from waiting list due to poor condition.
All patients removed from the waiting list in our study due
to deterioration of medical status were considered as if
they had died while on the waiting list. This appears to be
more accurate, since commonly these patients do not
return to the waiting list condition. However, the fact that
the better discrimination was achieved only in the univar-
iate analysis, whereas the c-statistics showed a strong
trend, but did not reach level of significance may limit the
conclusions of our retrospective evaluation.
Previous studies designated MELD scores as being better
prognostically for LTx. A prospective study of more than
3000 adult pre-LT patients with chronic liver disease
examined the outcome over a 3-months period. Within
three months of listing, 12% had died, and the 3-month
mortality was significantly larger in patients with higher
MELD scores. The c-statistic for 3-month mortality in this
study was 0.83 for the MELD score, significantly better in
comparison to 0.76 for the CTP score [11]. Another pro-
spective study evaluated baseline MELD and CTP scores to
predict 6-month mortality and 12-month mortality.
MELD discriminated better in this study as well [12].
However, several studies have also failed to confirm the
Table 5: Comparison of CTP and MELD scores: still on waiting 
list and no Tx
MELD <14.4 ≥14.4 Total
CTP
<9 84 14 98
≥9 17 24 41
101 38
Table 6: Comparison of CTP and MELD scores: died on or 
removed from the waiting list
MELD <14.4 ≥14.4 Total
CTP
<9 9 0 9
≥9 2 18 20
11 18
The errors bars are shown for the discrimination of patients by CTP (A) and MELD (B) sc es revealing a better cutoff forCTPFigure 1
The errors bars are shown for the discrimination of 
patients by CTP (A) and MELD (B) scores revealing a 
better cutoff for CTP.
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for patients on the waiting list. In the evaluation of the
hitherto largest cohort of almost 7000 patients with end
stage liver disease (listed as status 2A, 2B, and also status
3) showed that the CTP was slightly better, but not signif-
icantly different than MELD score in predicting 3-month
survival. This is somewhat surprising since these authors
extracted their data from the same UNOS database as the
one used in a previous trial [11]. In this study, status 3
patients were included, perhaps indicating that patients
with compensated cirrhosis are not adequately classified
by MELD [13]. This would be in line with our study,
which included status 3 patients as well. But in our study,
which analyzed a period of about one year, the CTP score
performed better than MELD in predicting death or
removal from waiting list. The data sets used were gener-
ated while waiting time was a major factor for organ allo-
cation within the alliance of Eurotransplant and MELD
score had not been implemented, this might explain the
fact that the mean MELD score of our study group at the
time of listing was comparatively low. During waiting
time MELD score increased then to levels, at which
patients benefit from transplantation [14].
Considering these 11 published studies, only four demon-
strated a statistical superiority of MELD over the CTP score
(approx. 4,500 patients), whereas seven showed no statis-
tical differences (approx. 8,000 patients). However, no
study showed MELD to be statistically inferior to CTP
score.
The MELD score has the advantage that it is based on a
multivariable analysis of objective tests for serum
bilirubin, INR and serum creatinine. Compared to CTP
score, it also includes assessment of renal function,
another major marker of the severity of the disease.
Though serum bilirubin, creatinine, and INR are usually
considered objective and therefore highly reliable, they
may also be influenced by therapeutic manipulations, not
only by disease progression. So one important advantage
of MELD, namely the independence of the subjective
judgment by a clinician, is counterbalanced in part by
arbitrary laboratory values. In our analysis creatinine was
not usable in discriminating patient groups. This might be
due to the fact, that impaired renal function only plays a
major role in short-term horizons. The very short life
expectancy of patients with hepatorenal syndrome is well
characterized. Or it could be due to the fact that creatinine
is not a very good marker for renal function in these
patients due to low body mass and partly peritoneal dial-
ysis in decompensated ascites.
Several attempts to improve the predictive ability of
MELD score were made by adding clinical variables
(hepatic encephalopathy, ascites) or laboratory parame-
ters (sodium), [15-18], the latter being the most promis-
ing [19], and the former forfeiting the benefit of objective
parameters.
Another effort to improve MELD involved analyzing the
change in MELD scores over time, bearing in mind that
this dynamic variable would reflect the dynamic of dis-
ease in this patient. In a retrospective evaluation of 760
patients the delta MELD score had better prediction abil-
ity for mortality than the baseline MELD score [20]. How-
ever, a retrospective evaluation found the delta MELD
score to be less predictive compared with the most up-to-
date MELD score [21]. In another study, the delta MELD
score per month at 6 and 12 months was significantly bet-
ter compared with baseline the MELD and CTP [12]. In
our trial, the change in MELD score was not superior in
predicting survival or the need for removal from the wait-
ing list compared to baseline MELD (data not shown).
In comparison to other studies, we analyzed not only
death on the waiting list but also well removal from the
waiting list due to poor condition; additionally, we
extended the patient observation time over a period of
one year. This may help to explain the differences of our
results compared to other studies. But more importantly,
from our point of view, this combined end point more
accurately reflects the natural history of disease and its
reality in our center. However, the MELD score is estab-
lished for the 3 months period, which may be the most
important time frame for allocation. Our data do not
argue against the use of MELD concerning priorization of
patients during the initial period on the waiting list. But
The ROC curve shows the performance of the CTP score (AU  0.73) compared to the MELD score (AUROC 0.68)Figure 2
The ROC curve shows the performance of the CTP 
score (AUROC 0.73) compared to the MELD score 
(AUROC 0.68).Page 6 of 7
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serve as an additional factor for assessment of patient
prognosis. Furthermore, since our data suggest that some
aspects of prognosis of cirrhosis are better reflected by CTP
score, they might assist in the development of new scoring
systems for allocation.
Conclusion
The increasing numbers of standard exceptions for MELD
scores, for example cholestatic diseases, reflect the clinical
need to improve this allocation system. Although our
study does not argue against the use of the MELD score for
short term allocation of organs and priorization of recipi-
ents, the long term prediction of mortality or removal
from waiting list in patients awaiting liver transplantation
might be better assessed by the CTP score than the MELD
score. This might have implications for the development
of new improved scoring systems.
List of abbreviations
CTP: Child-Turcotte-Pugh; LTx: liver transplantation;
MELD: Model of End-Stage Liver Disease; TIPS: transjugu-
lar intra-hepatic porto-systemic shunt.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
DG took part in designing the study, analyzing the data
and writing the manuscript. KHW took part in designing
the study, gathering the data and writing the manuscript.
MB took part in gathering the data and writing the manu-
script. AZ took part in gathering the data and writing the
manuscript. WS and JS took part in designing the study
and writing the manuscript. TB took part in statistical
analysis and writing the manuscript. PS took part in
designing the study, analyzing the data and writing the
manuscript. All authors read and approved the final man-
uscript.
Acknowledgements
We would like to thank Norbert Hillebrand for compiling the listing data of 
the patients and Heather Karner for critically reading the manuscript.
References
1. Christensen E: Prognostic models including the Child-Pugh,
MELD and Mayo risk scores--where are we and where should
we go?  J Hepatol 2004, 41:344-50.
2. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R:
Transection of the oesophagus for bleeding oesophageal
varices.  Br J Surg 1973, 60:646-9.
3. Durand F, Valla D: Assessment of the prognosis of cirrhosis:
Child-Pugh versus MELD.  J Hepatol 2005, 42(Suppl):S100-7.
4. Wiesner RH: Patient selection in an era of donor liver short-
age: current US policy.  Nat Clin Pract Gastroenterol Hepatol 2005,
2:24-30.
5. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC:
A model to predict poor survival in patients undergoing
transjugular intrahepatic portosystemic shunts.  Hepatology
2000, 31:864-71.
6. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM,
Kosberg CL, D'Amico G, Dickson ER, Kim WR: A model to pre-
dict survival in patients with end-stage liver disease.  Hepatol-
ogy 2001, 33:464-70.
7. Cholongitas E, Marelli L, Kerry A, Senzolo M, Goodier DW, Nair D,
Thomas M, Patch D, Burroughs AK: Different methods of creati-
nine measurement significantly affect MELD scores.  Liver
Transpl 2007, 13:523-9.
8. Robert A, Chazouilleres O: Prothrombin time in liver failure:
time, ratio, activity percentage, or international normalized
ratio?  Hepatology 1996, 24:1392-4.
9. Trotter JF, Brimhall B, Arjal R, Phillips C: Specific laboratory
methodologies achieve higher model for endstage liver dis-
ease (MELD) scores for patients listed for liver transplanta-
tion.  Liver Transpl 2004, 10:995-1000.
10. Fink MA, Berry SR, Gow PJ, Angus PW, Wang BZ, Muralidharan V,
Christophi C, Jones RM: Risk factors for liver transplantation
waiting list mortality.  J Gastroenterol Hepatol 2007, 22:119-24.
11. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kre-
mers W, Lake J, Howard T, Merion RM, et al.: Model for end-stage
liver disease (MELD) and allocation of donor livers.  Gastroen-
terology 2003, 124:91-6.
12. Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Lee PC, Chang FY, Lee SD:
Evaluation of the increase in model for end-stage liver dis-
ease (DeltaMELD) score over time as a prognostic predictor
in patients with advanced cirrhosis: risk factor analysis and
comparison with initial MELD and Child-Turcotte-Pugh
score.  J Hepatol 2005, 42:826-32.
13. Heuman DM, Mihas A: Utility of the MELD score for assessing
3-month survival in patients with liver cirrhosis: one more
positive answer.  Gastroenterology 2003, 125:992-3. author reply
994-5
14. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe
RA: The survival benefit of liver transplantation.  Am J Trans-
plant 2005, 5:307-13.
15. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil
FG: Addition of serum sodium into the MELD score predicts
waiting list mortality better than MELD alone.  Liver Transpl
2005, 11:336-43.
16. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey
MR: Model for end stage liver disease score predicts mortal-
ity across a broad spectrum of liver disease.  J Hepatol 2004,
40:897-903.
17. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault
NA: Serum sodium predicts mortality in patients listed for
liver transplantation.  Hepatology 2005, 41:32-9.
18. Heuman DM, Abou-Assi SG, Habib A, Williams LM, Stravitz RT, San-
yal AJ, Fisher RA, Mihas AA: Persistent ascites and low serum
sodium identify patients with cirrhosis and low MELD scores
who are at high risk for early death.  Hepatology 2004, 40:802-10.
19. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson
JT, Edwards E, Therneau TM: Hyponatremia and mortality
among patients on the liver-transplant waiting list.  N Engl J
Med 2008, 359:1018-26.
20. Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held
PJ: Longitudinal assessment of mortality risk among candi-
dates for liver transplantation.  Liver Transpl 2003, 9:12-8.
21. Bambha K, Kim WR, Kremers WK, Therneau TM, Kamath PS, Wies-
ner R, Rosen CB, Thostenson J, Benson JT, Dickson ER: Predicting
survival among patients listed for liver transplantation: an
assessment of serial MELD measurements.  Am J Transplant
2004, 4:1798-804.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-230X/9/72/pre
pubPage 7 of 7
(page number not for citation purposes)
